Table 1.
Patient characteristics
| Characteristic | No. (%) (n=31) |
|---|---|
| Age (yr), median (range) | 59 (38–74) |
| Sex | |
| Male | 25 (80.6) |
| Female | 6 (19.4) |
| ECOG PS | |
| 1 | 27 (87.1) |
| 2 | 4 (12.9) |
| Primary tumor location | |
| Oral cavity | 6 (19.4) |
| Oropharynx | 5 (16.1) |
| Hypopharynx | 4 (12.9) |
| Larynx | 4 (12.9) |
| Othera) | 12 (38.7) |
| Stage | |
| Recurrent | 1 (3.2) |
| Metastatic | 30 (96.8) |
| Distant metastasis site | |
| Lung | 11 (35.5) |
| Bone | 6 (19.4) |
| Brain | 3 (9.7) |
| Liver | 3 (9.7) |
| No. of prior chemotherapy regimens, median (range) | 2 (1–7) |
| No. of prior radiotherapy treatments, median (range) | 1 (0–9)b) |
| History of CCRT | 21 (67.7) |
| PD-L1 TC ≥ 1% | |
| Negative | 17 (54.8) |
| Positive | 8 (25.8) |
| Unknown | 6 (19.4) |
CCRT, concurrent chemoradiation; ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1 TC, programmed cell death ligand 1 tumor cell.
a)
Nasal cavity cancer, maxillary sinus cancer, auditory canal cancer, lacrimal sac cancer,
b)
Except for one patient, all patients had a history of radio-therapy.